^
    Back
    Association details:
    Biomarker:miR-126-3p overexpression
    Cancer:Hepatocellular Cancer
    Drug:sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Ann Transl Med
    Title:

    miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1

    Excerpt:
    HCC cells with high expression of miR-126-3p exhibited increased resistance to sorafenib.
    DOI:
    10.21037/atm-20-2081